Group One Trading’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.19M | Sell |
172,100
-160,800
| -48% | -$8.48M | 0.02% | 970 |
|
|
2025
Q4 | $17.5M | Buy |
332,900
+90,400
| +37% | +$5.41M | 0.03% | 623 |
|
|
2025
Q3 | $15.7M | Sell |
242,500
-200,300
| -45% | -$11.5M | 0.03% | 621 |
|
|
2025
Q2 | $21.5M | Buy |
442,800
+118,400
| +36% | +$4.58M | 0.05% | 393 |
|
|
2025
Q1 | $11M | Buy |
324,400
+155,500
| +92% | +$6.59M | 0.03% | 584 |
|
|
2024
Q4 | $6.65M | Buy |
168,900
+60,000
| +55% | +$2.83M | 0.02% | 957 |
|
|
2024
Q3 | $5.12M | Buy |
108,900
+20,600
| +23% | +$1.05M | 0.01% | 986 |
|
|
2024
Q2 | $4.77M | Sell |
88,300
-61,500
| -41% | -$3.56M | 0.02% | 828 |
|
|
2024
Q1 | $10.2M | Sell |
149,800
-217,600
| -59% | -$15.6M | 0.04% | 428 |
|
|
2023
Q4 | $23M | Buy |
367,400
+307,300
| +511% | +$17M | 0.06% | 296 |
|
|
2023
Q3 | $2.73M | Sell |
60,100
-16,700
| -22% | -$862K | 0.01% | 1383 |
|
|
2023
Q2 | $4.31M | Buy |
76,800
+16,000
| +26% | +$908K | 0.01% | 1074 |
|
|
2023
Q1 | $2.75M | Sell |
60,800
-138,900
| -70% | -$6.75M | 0.01% | 1268 |
|
|
2022
Q4 | $8.12M | Sell |
199,700
-16,100
| -7% | -$854K | 0.02% | 856 |
|
|
2022
Q3 | $14.1M | Buy |
215,800
+7,100
| +3% | +$515K | 0.03% | 545 |
|
|
2022
Q2 | $12.7M | Sell |
208,700
-66,200
| -24% | -$3.89M | 0.02% | 705 |
|
|
2022
Q1 | $17.3M | Sell |
274,900
-550,800
| -67% | -$34.6M | 0.02% | 683 |
|
|
2021
Q4 | $62.6M | Sell |
825,700
-114,200
| -12% | -$9.98M | 0.05% | 257 |
|
|
2021
Q3 | $105M | Buy |
939,900
+227,900
| +32% | +$28.6M | 0.11% | 114 |
|
|
2021
Q2 | $115M | Sell |
712,000
-69,300
| -9% | -$8.43M | 0.14% | 92 |
|
|
2021
Q1 | $95.2M | Buy |
781,300
+337,000
| +76% | +$50.9M | 0.14% | 98 |
|
|
2020
Q4 | $68M | Buy |
444,300
+388,600
| +698% | +$45.9M | 0.12% | 123 |
|
|
2020
Q3 | $4.66M | Sell |
55,700
-4,700
| -8% | -$417K | 0.01% | 968 |
|
|
2020
Q2 | $4.44M | Buy |
60,400
+5,300
| +10% | +$310K | 0.02% | 886 |
|
|
2020
Q1 | $2.34M | Sell |
55,100
-243,200
| -82% | -$12.6M | 0.02% | 941 |
|
|
2019
Q4 | $18.2M | Buy |
298,300
+244,500
| +454% | +$13.3M | 0.12% | 169 |
|
|
2019
Q3 | $2.21M | Buy |
53,800
+16,300
| +43% | +$779K | 0.02% | 1138 |
|
|
2019
Q2 | $1.77M | Sell |
37,500
-2,400
| -6% | -$95.9K | 0.02% | 1166 |
|
|
2019
Q1 | $1.43M | Sell |
39,900
-15,500
| -28% | -$536K | 0.02% | 1163 |
|
|
2018
Q4 | $1.58M | Buy |
55,400
+9,400
| +20% | +$327K | 0.01% | 1179 |
|
|
2018
Q3 | $2.04M | Buy |
46,000
+23,900
| +108% | +$1.25M | 0.02% | 1150 |
|
|
2018
Q2 | $1.3M | Sell |
22,100
-2,500
| -10% | -$142K | 0.01% | 1465 |
|
|
2018
Q1 | $1.12M | Buy |
24,600
+24,400
| +12,200% | +$1.01M | 0.01% | 1434 |
|
|
2017
Q4 | $5K | Buy |
+200
| New | +$3.8K | ﹤0.01% | 4554 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Group One Trading's CRSP Position: Q1 2026 in Review
Group One Trading increased its CRISPR Therapeutics (CRSP) stake by 2.2% in Q1 2026, buying an estimated $108K and bringing the position to 96,001 shares worth $4.57M. The position accounts for 0.01% of the portfolio, ranked #1370.
Group One Trading first reported a position in CRSP in Q4 2017 and has held it in 26 quarters since. The position peaked at $64.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Group One Trading held 96,001 shares of CRISPR Therapeutics worth $4.57M as of Q1 2026.
- Group One Trading bought 2,047 CRISPR Therapeutics shares in Q1 2026, an estimated $108K.
- CRISPR Therapeutics made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1370 holding.
- Group One Trading first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 26 quarters since.
- Group One Trading's CRISPR Therapeutics position peaked at $64.7M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.